Use of carcinogen-DNA and carcinogen-protein adduct biomarkers for cohort selection and as modifiable end points in chemoprevention trials.

IARC scientific publications

Volumn , Issue 139, 1996, Pages 237-248

  Kensler, T W ^a   Groopman, J D ^a   Wogan, G N ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOGEN; DNA; PLASMA PROTEIN; TUMOR MARKER;

CHEMOPROPHYLAXIS; CLINICAL TRIAL; DNA ADDUCT; DRUG EFFECT; HUMAN; METABOLISM; METHODOLOGY; REVIEW;

ANTICARCINOGENIC AGENTS; BLOOD PROTEINS; CARCINOGENS; CHEMOPREVENTION; CLINICAL TRIALS; DNA; DNA ADDUCTS; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030330884     PISSN: 03005038     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)